Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan, John Gerry
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. [electronic resource] - Annals of the rheumatic diseases Jul 2017 - 1219-1227 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1468-2060
10.1136/annrheumdis-2016-210236 doi
Adult
Aged
Antihypertensive Agents--therapeutic use
Disease Progression
Double-Blind Method
Drug Therapy, Combination
Edema--chemically induced
Female
Humans
Hypertension, Pulmonary--drug therapy
Lupus Erythematosus, Systemic--complications
Male
Middle Aged
Mixed Connective Tissue Disease--complications
Phenylpropionates--therapeutic use
Phosphodiesterase 5 Inhibitors--therapeutic use
Pyridazines--therapeutic use
Scleroderma, Systemic--complications
Tadalafil--therapeutic use
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. [electronic resource] - Annals of the rheumatic diseases Jul 2017 - 1219-1227 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1468-2060
10.1136/annrheumdis-2016-210236 doi
Adult
Aged
Antihypertensive Agents--therapeutic use
Disease Progression
Double-Blind Method
Drug Therapy, Combination
Edema--chemically induced
Female
Humans
Hypertension, Pulmonary--drug therapy
Lupus Erythematosus, Systemic--complications
Male
Middle Aged
Mixed Connective Tissue Disease--complications
Phenylpropionates--therapeutic use
Phosphodiesterase 5 Inhibitors--therapeutic use
Pyridazines--therapeutic use
Scleroderma, Systemic--complications
Tadalafil--therapeutic use